98%
921
2 minutes
20
Background And Aims: Identification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal. Therefore, the ELIMINATE(ELIMINation of HCV in AusTria East) project aimed to systematically re-link people with a 'last-positive' HCV-RNA PCR record to care.
Methods: In 10 major liver centres in Eastern Austria, a systematic readout of 'last-positive' HCV-RNA PCR test records obtained between 2008 and 2020 were conducted and linked to available patient contact data. Between 2020 and 2023, individuals were contacted first by phone, then by letter, to inform them about the availability of effective direct-acting antiviral (DAA) treatment and invite them for pre-treatment evaluation.
Results: The overall cohort of last-positive HCV+ individuals included 5695 subjects (62.5% males, mean age 57.3 ± 17.3 years); of note, 1931 (34%) of them had died and 759 (13%) individuals had no valid contact information. Of the remaining 3005 individuals, 1171 (40.0%) had already achieved sustained virological response (SVR) at the time of re-call. We successfully reached 617 (20.5%), of whom 417 (67.6%) attended their pre-treatment visit, and 397 (64.3%) commenced DAA-therapy. HCV cure has been confirmed in 326 individuals, corresponding to an SVR rate of 82.1%.
Conclusion: The ELIMINATE project identified 5695 people living with HCV who were 'lost to care' despite documented HCV viraemia. While invalid contact data were an evident barrier to HCV elimination, premature deaths among the cohort underscored the severity of untreated HCV. The implementation of a systematic HCV-RNA PCR recorded-based re-call workflow represents an effective strategy supporting the WHO goal of HCV elimination.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586887 | PMC |
http://dx.doi.org/10.1111/liv.16076 | DOI Listing |
Clin Exp Hepatol
June 2025
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Aim Of The Study: To analyze long-term epidemiological patterns and trends in the burden of infection and mortality due to viral hepatitis in Poland before and during the COVID-19 pandemic.
Material And Methods: Data for the burden of the most common viral hepatitis types (HAV, HBV ±HDV, HCV, and HEV) over 2009-2023 were extracted from the national registries in Poland. The joinpoint regression model was used to analyze trends in viral hepatitis infections and mortality.
J Formos Med Assoc
September 2025
Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan
Since 2010, high-risk sexual contact has become a major route of hepatitis C virus (HCV) transmission in Taiwan, particularly among men who have sex with men (MSM). With the rollout of direct-acting antivirals (DAAs) and the implementation of national strategies such as mass screening and reflex viral load testing to improve detection of HCV viremia, Taiwan has made substantial progress toward HCV elimination. Among MSM living with HIV, the prevalence, incidence, and reinfection rates of HCV have significantly declined following the implementation of the HCV elimination program.
View Article and Find Full Text PDFBackground HIV and Hepatitis C (HCV) are blood borne infections (BBIs) that remain a significant cause of global morbidity and mortality among people who inject drugs (PWID). UNAIDS and WHO have set goals for the elimination of viral hepatitis and HIV as major public health threats by 2030. To achieve these targets, innovative strategies are required among marginalized populations such as PWID, especially in resource-limited countries where coverage of harm reduction services is often limited.
View Article and Find Full Text PDFOpen Forum Infect Dis
August 2025
Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
Background: People with human immunodeficiency virus (HIV; PWH) are at increased risk of hepatitis C virus (HCV) coinfection and experiencing negative clinical outcomes. We evaluated direct-acting antiviral (DAA) initiation among PWH with HCV to identify factors associated with initiation.
Methods: US and Canadian PWH ≥18 years with a detectable HCV RNA in the North American AIDS Cohort Collaboration on Research and Design were followed up from the latest of first detectable HCV viremia, antiretroviral therapy initiation, enrollment date, or 1 January 2014 until the first of DAA prescription, clearance of HCV viremia, loss to follow-up, death, or 31 December 2021.
Can Commun Dis Rep
July 2025
Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are sexually transmitted and blood-borne infections that Canada is committed to eliminate as public health concerns. Accurate epidemiological estimates require cross-sectional data as input. The objective of this study was to estimate the prevalence of present HBV infection (hepatitis B surface antigen-positive) and proportion aware of their infection, the vaccine-induced HBV immunity, the prevalence of HCV antibodies (anti-HCV-positive), the prevalence of present HCV infection (RNA-positive) and proportion aware of their infection, in the household population in Canada.
View Article and Find Full Text PDF